![]() ![]() |
|
![]() |
|
Clinical Image
| ||||||
| Unusual serpentine supravenous hyperpigmentation during chemotherapy treatment | ||||||
| Houda Mouzount1, Sihame Lkhouyaali1, Saber Boutayeb1, Hassan Errihani1 | ||||||
|
1MD, National institute of oncology, Department of Medical Oncology, Rabat, Morocco.
| ||||||
| ||||||
|
[HTML Abstract]
[PDF Full Text]
[Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar]
|
| How to cite this article: |
| Mouzount H, Lkhouyaali S, Boutayeb S, Errihani H. Unusual serpentine supravenous hyperpigmentation during chemotherapy treatment. International Journal of Case Reports and Images; 20134(4):241–242. |
|
Case Report
| ||||||
|
A 54-year-old female patient diagnosed for inoperable colic adenocarcinoma with multiple liver metastases in January 2011. She was treated by first line fluorouracil and irinotecan-based chemotherapy in combination with bevacizumab. After three cycles of chemotherapy, a good response to treatment were observed and the patient did not show cutaneous toxicity, the treatment was continued. Two days after the seventh cycle, the patient noticed for the first time asymptomatic pigmentation retracing venous streak of right and left arms, from forearms to shoulders. Clinical examination revealed serpiginous hyperpigmented streaks along the course of the superficial veins. (Figure 1A) There were no apparent leakages of medical agents in surrounding skin and no other mucocutaneous abnormalities. No history of extravasation or phlebitis preceded the hyperpigmentation. For this patient, the chemotherapy was suspended and no other treatment was added. After two weeks, we noticed remarkable reduction in hyperpigmented lesions. (Figure 1B) Fluorouracil was replaced by capecitabine. Two months later, this complication was completely resolved. | ||||||
| ||||||
|
Discussion | ||||||
|
Serpentine supravenous hyperpigmentation was first described in 1976 by Hrushesky as an uncommon side effect of intraveinous fluorouracil. [1] Other chemotherapeutic agents, such as vinorelbine, fotemustine, and docetaxel, have also been found to cause serpentine supravenous hyperpigmentation. [2] In a recent study, skin hyperpigmentation occurred in 26% of patients treated by fluorouracil. However, linear hyperpigmented streaks over the arm veins used for injections without previous erythematous changes have rarely been reported. [3] Its exact mechanism of pigment induction is unknown. [4] Some hypotheses suggest that these cytotoxic drugs cause loss of endothelial integrity. This would permit the leakage of agent from the vessel to the overlying epidermis where it interferes with melanogenesis thus resulting in hyperpigmentation. [2] [4] No specific treatment is recommended. Pigmentation promptly subsides once the offending drug is stopped. [4] | ||||||
|
Conclusion
| ||||||
|
Serpentine supravenous hyperpigmentation can be prevented by avoiding peripheral infusion of some chemotherapy agents, especially fluorouracil, by using permanent central-infusion catheter or suggesting oral chemotherapy if possible. | ||||||
|
Acknowledgements
| ||||||
|
We aknowledge Professor Youssef Bakri for his critical review. | ||||||
|
References
| ||||||
| ||||||
|
[HTML Abstract]
[PDF Full Text]
|
|
Author Contributions
Houda Mouzount – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Sihame Lkhouyaali – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published Saber Boutayeb – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published Hassan Errihani – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published |
|
Guarantor of submission
The corresponding author is the guarantor of submission. |
|
Source of support
None |
|
Conflict of interest
Authors declare no conflict of interest. |
|
Copyright
© Houda Mouzount et al. 2013; This article is distributed the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any means provided the original authors and original publisher are properly credited. (Please see Copyright Policy for more information.) |
|
|